We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

149 hedge funds and large institutions have $1.31B invested in Eagle Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

12% more call options, than puts

Call options by funds: $20.7M | Put options by funds: $18.4M

12% more capital invested

Capital invested by funds: $1.17B → $1.31B (+$136M)

9% more funds holding

Funds holding: 137 → 149 (+12)

4% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
149
Holders Change
+12
Holders Change %
+8.76%
% of All Funds
3.72%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
31
Increased
48
Reduced
46
Closed
16
Calls
$20.7M
Puts
$18.4M
Net Calls
+$2.23M
Net Calls Change
-$8.96M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$12.6M
2
CM
Castleark Management
Illinois
+$8.46M
3
State Street
State Street
Massachusetts
+$6.87M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.68M
5
BFA
BlackRock Fund Advisors
California
+$6.06M

Top Sellers

Rank Fund Capital Flow
1
PAI
ProQuest Associates IV
Florida
-$31.3M
2
O
OrbiMed
New York
-$26.5M
3
PC
PointState Capital
New York
-$21.3M
4
JCI
Jet Capital Investors
New York
-$9.44M
5
Morgan Stanley
Morgan Stanley
New York
-$8.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
GAM
26
Gotham Asset Management
New York
$6.94M +$3.48M +47,951 +121%
William Blair & Company
27
William Blair & Company
Illinois
$6.38M -$160K -2,200 -3%
Millennium Management
28
Millennium Management
New York
$5.97M +$5.46M +75,232 New
PC
29
Pier Capital
Connecticut
$5.96M -$1.4M -19,213 -20%
Citigroup
30
Citigroup
New York
$5.89M +$4.82M +66,303 +831%
Norges Bank
31
Norges Bank
Norway
$5.63M – – –
Geode Capital Management
32
Geode Capital Management
Massachusetts
$5.61M +$168K +2,316 +3%
BIA
33
Biondo Investment Advisors
Pennsylvania
$5.04M +$4.62M +63,575 New
CS
34
Candriam SCA
Luxembourg
$4.92M -$363K -5,000 -7%
Principal Financial Group
35
Principal Financial Group
Iowa
$4.61M +$1.38K +19 +0%
PAM
36
Panagora Asset Management
Massachusetts
$4.58M +$51.1K +704 +1%
CWG
37
C WorldWide Group
Denmark
$4.25M -$2.17M -29,807 -36%
OM
38
Opaleye Management
Massachusetts
$3.97M -$1.45M -20,000 -29%
QI
39
QS Investors
New York
$3.88M -$815K -11,215 -19%
CIP
40
Chartwell Investment Partners
Pennsylvania
$3.87M +$3.54M +48,739 New
BIM
41
BlackRock Investment Management
Delaware
$3.43M +$517K +7,124 +20%
BG
42
Bellevue Group
Switzerland
$3.23M +$850K +11,700 +40%
Goldman Sachs
43
Goldman Sachs
New York
$3.21M +$985K +13,555 +50%
IAM
44
Iridian Asset Management
Connecticut
$3.15M +$908K +12,500 +46%
GC
45
Guggenheim Capital
Illinois
$3.12M -$2.6M -35,814 -48%
NIP
46
Nicholas Investment Partners
California
$2.95M +$2.71M +37,254 New
EI
47
EAM Investors
California
$2.94M +$2.7M +37,106 New
CS
48
Credit Suisse
Switzerland
$2.85M +$64.4K +887 +3%
Charles Schwab
49
Charles Schwab
California
$2.73M -$20.1K -277 -0.8%
Barclays
50
Barclays
United Kingdom
$2.68M -$2.24M -30,826 -48%
1
2
3 4 5

EGRX Hedge Fund Activity: Q4 2016 in Review

149 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2016, worth a combined $1.31B — up 12% from $1.17B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EGRX positions and 16 closed out — a net gain of 15 holders — while 48 added to existing stakes and 46 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $12.6M. The largest seller was ProQuest Associates IV, cutting an estimated $31.3M.

  • 149 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2016, up from 137 in Q3 2016.
  • Funds reported $1.31B of Eagle Pharmaceuticals, Inc. stock for Q4 2016, up 12% quarter-over-quarter.
  • 31 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2016 and 16 closed out, a net change of +15 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2016 was Victory Capital Management, an estimated $12.6M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q4 2016 was ProQuest Associates IV, an estimated $31.3M sold.

Based on aggregated 13F filings for Q4 2016.